FOS and myeloid sarcoma: FOS may have essential regulatory roles in modulating gene expression in the pathophysiology of MS (Liu et al., 2013; Kotelnikova et al., 2015), as well as in the mechanism of action of IFNbeta1a and fingolimod (Howe et al., 2006; Kauffman et al., 2009; Yester et al., 2015; Anastasiadou and Knöll, 2016; Groves et al., 2018; Tran et al., 2020).